Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany.
Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee, Scotland DD1 5JJ, U.K.
J Med Chem. 2023 Sep 28;66(18):12776-12811. doi: 10.1021/acs.jmedchem.3c00434. Epub 2023 Sep 14.
Hypoxia-inducible factor-1α (HIF-1α) constitutes the principal mediator of cellular adaptation to hypoxia in humans. The HIF-1α protein level and activity are tightly regulated by the ubiquitin E3 ligase von Hippel-Lindau (VHL). Here, we performed a structure-guided and bioactivity-driven design of new VHL inhibitors. Our iterative and combinatorial strategy focused on chemical variability at the phenylene unit and encompassed further points of diversity. The exploitation of tailored phenylene fragments and the stereoselective installation of the benzylic methyl group provided potent VHL ligands. Three high-resolution structures of VHL-ligand complexes were determined, and bioactive conformations of these ligands were explored. The most potent inhibitor () exhibited dissociation constants lower than 40 nM, independently determined by fluorescence polarization and surface plasmon resonance and an enhanced cellular potency, as evidenced by its superior ability to induce HIF-1α transcriptional activity. Our work is anticipated to inspire future efforts toward HIF-1α stabilizers and new ligands for proteolysis-targeting chimera (PROTAC) degraders.
缺氧诱导因子-1α(HIF-1α)是人类细胞对缺氧适应的主要介质。HIF-1α 蛋白水平和活性受到泛素 E3 连接酶 von Hippel-Lindau(VHL)的严格调节。在这里,我们进行了基于结构和基于生物活性的新型 VHL 抑制剂设计。我们的迭代和组合策略专注于苯环单元的化学可变性,并包含了更多的多样性点。定制苯环片段的利用和苄基甲基的立体选择性安装提供了有效的 VHL 配体。确定了三个 VHL-配体复合物的高分辨率结构,并探索了这些配体的生物活性构象。最有效的抑制剂()表现出低于 40 nM 的解离常数,这是通过荧光偏振和表面等离子体共振独立确定的,并且具有增强的细胞效力,这表现为其诱导 HIF-1α 转录活性的能力更优。我们的工作预计将激发未来对 HIF-1α 稳定剂和新的 PROTAC 降解剂配体的研究。